CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 593 enrolled
Drug / intervention
tinidazole, metronidazoledrug
Likely dose
Tinidazole 500 mg twice daily or Metronidazole 500 mg twice dailyAI-extracted
Key inclusion· 4
  • ✓Women at least 18 years of age
  • ✓Symptoms of vaginal odor and/or discharge
  • ✓Meet clinical (Amsel) criteria for bacterial vaginosis
  • ✓Willing to participate in research
Key exclusion· 6
  • ✕Presence of another vaginal infection or sexually transmitted disease
  • ✕Allergy to metronidazole
  • ✕Pregnant or nursing
  • ✕Oral or intravaginal antibiotics within the past 2 weeks

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00334633
NCT00334633Phase 4Completed
CompareCT.gov

Tinidazole for the Treatment of Bacterial Vaginosis

University of Alabama at Birmingham·interventional·Posted Jun 8, 2006·Updated Dec 2, 2017

In Brief

A Phase 4 clinical trial evaluating tinidazole, metronidazole for Bacterial Vaginosis. Completed, enrolled 593 participants across 1 site.

Detailed Summary

We are trying to determine if treatment of bacterial vaginosis with tinidazole is better than treatment with metronidazole

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBacterial Vaginosis
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 8, 2006
Enrollment StartNov 1, 2004
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 20.1 years ago

Interventions

tinidazole, metronidazoledrug

Tinidazole 500 mg bid; Tinidazole 1mg bid; Metronidazole 500mg bid